Federal initiatives to accelerate psychedelic-based therapies for mental health and substance use disorders are advancing, with multiple agencies taking coordinated steps this week. The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including leading institutions such as Johns Hopkins University and other innovators focused on psychedelic science.
FDA Regulatory Actions
The U.S. Food and Drug Administration granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, highlighting continued expansion of clinical-stage programs in the mental health space. The FDA issued three Commissioner’s National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a clear intent to accelerate high-impact therapies. The inclusion of a PTSD-relevant program signals a strong institutional focus on addressing urgent unmet needs among veterans and broader patient populations.
The FDA confirmed that final guidance for psychedelic drug development will be published imminently, a long-anticipated milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways.
Silo Pharma’s Position
Silo Pharma, Inc., a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, commended the wave of federal actions. Silo CEO Eric Weisblum stated: “We are witnessing a coordinated and accelerating shift at the federal level. From funding and clinical advancement to regulatory prioritization, in our opinion the foundation is being laid for a new generation of therapies that could transform how we treat PTSD and related disorders.” Silo’s therapeutic portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/gnwcq-2026-4-29-silo-pharmas-ptsd-program-advances-as-fda-fast-tracks-psychedelic-therapies-for-ptsd